Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Feb 2017

Rogers Laura M, Mott Sarah L, Smith Brian J, Link Brian K, Sahin Deniz, Weiner George J

Abstract excerpt

Purpose: Anti-CD20 mAb therapies, including rituximab and obinutuzumab (GA101), are common treatments for follicular lymphoma. In an effort to better understand the role of complement in mAb action, we recently performed germline SNP profiling on 142 follicular lymphoma patients and found rs3766404 genotype correlated with patient response to rituximab. To assess the role of three SNP-associated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antigens, CD20

Share to Biomarkers, Pharmacological

Share to Blood Proteins

Share to Complement C3b Inactivator Proteins

Share to Complement System Proteins

Share to Lymphoma, Follicular

Share to Rituximab

Source

Open in PubMed Open full text

Identifiers

PMID: 27528699
DOI: 10.1158/1078-0432.CCR-16-1275
PMCID: PMC5311060

Genes

CFHR3
CFHR1
CFH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.PMID 27528699Read ↗

Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma.Semantic proximity Read ↗

Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.Semantic proximity Read ↗

Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.Semantic proximity Read ↗

FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.Semantic proximity Read ↗

IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodiesSemantic proximity Read ↗

IRF8 regulates efficacy of therapeutic anti‐CD20 monoclonal antibodiesSemantic proximity Read ↗

Impact of FCGR2A and FCGR3A Gene Variants on the Response to Rituximab in Patients With Glomerular Diseases.Semantic proximity Read ↗

Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.Semantic proximity Read ↗

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.Semantic proximity Read ↗

Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59Semantic proximity Read ↗

Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma.Semantic proximity Read ↗

Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular CytotoxicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.